ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United ...

Vertex Ventures ramps up India investments, targeting AI, fintech, and consumer brands. With a $541M fund, it focuses on ...

Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.92% to $485.89 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research ...

Learn more about whether Alkami Technology, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Vertex Pharmaceuticals Inc. closed 8.54% short of its 52-week high of $519.88, which the company achieved on November 8th.

Las Vegas is playing host to Google Cloud Next 2025, an event unfolding at a critical moment for the technology industry. The ...

UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced at Google Cloud Next 2025 the launch of its generative AI-based UiPath Medical Record Summarization agent, ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along ...